David Dickson
About David Dickson
David Dickson serves as the Director of CMC at Venatorx Pharmaceuticals, Inc., where he manages drug substance development and regulatory submissions. He has extensive experience in the pharmaceutical industry, having held various positions at companies such as DuPont, Teva Specialty Pharmaceuticals, and Bayer HealthCare.
Work at Venatorx Pharmaceuticals
David Dickson currently serves as the Director of CMC at Venatorx Pharmaceuticals, Inc., a position he has held since 2023. In this role, he leads external drug substance development and manages relationships with Contract Development and Manufacturing Organizations (CDMOs). His responsibilities include overseeing strategic technical development and ensuring compliance with ICH, EU, and FDA quality guidelines. Prior to his current role, he worked as Associate Director CMC at Venatorx from 2021 to 2023, where he managed process development and commercial manufacturing for the VNRX-7145 and VNRX-5133 programs.
Education and Expertise
David Dickson earned his Ph.D. in Organic Synthesis from the University of Illinois Chicago, where he studied from 2003 to 2008. He also holds a Master of Science in Organic and Organometallic Chemistry from UC Santa Barbara, completed between 1996 and 1998. His academic background is complemented by a Bachelor of Science in Chemistry from California State University, Chico, obtained from 1991 to 1996. This educational foundation supports his expertise in drug substance development and regulatory compliance.
Background in Pharmaceutical Research
David Dickson has extensive experience in pharmaceutical research and development. He worked at DuPont as a Research Investigator from 2010 to 2014 and held various positions in the Greater Philadelphia Area, including Director of Process Development at Abzena from 2018 to 2021 and Scientist at Teva Specialty Pharmaceuticals from 2015 to 2018. His earlier career includes a role as a Postdoctoral Scholar at The University of Chicago from 2009 to 2010 and as a Sr. Associate Scientist I at Bayer HealthCare from 1999 to 2003.
Achievements in Drug Development
Throughout his career, David Dickson has critically reviewed and drafted CMC regulatory documents, including IND and NDA submissions. He has ensured the delivery of drug substances from external manufacturing campaigns while adhering to regulatory quality guidelines. His role at Venatorx Pharmaceuticals involved analyzing process and analytical data to resolve synthetic challenges during drug substance development and participating in budget planning for drug substance expenditures.